



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring MD 20993

NDA 22-454

**NDA APPROVAL**

GE Healthcare  
Attention: Allison Mueller  
Head of Americas, Regulatory Affairs  
101 Carnegie Center  
Princeton, NJ 08540-6231

Dear Ms. Mueller:

Please refer to your New Drug Application (NDA) dated March 6, 2009, received March 9, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for DaTscan (Ioflupane I 123) Injection.

We acknowledge receipt of your amendments dated November 16, December 30, 2010, January 6, and 12, 2011.

The November 16, 2010, submission constituted a complete response to our December 23, 2009, action letter.

This new drug application provides for the use of DaTscan (Ioflupane I 123) Injection for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian Syndromes (PS).

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

**CARTON AND IMMEDIATE CONTAINER LABELS**

We acknowledge your January 12, 2011, submission containing final printed carton and container labels.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable and because the disease/condition does not exist in children.

**POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B**

We remind you of your postmarketing commitment, which you agreed to conduct in your November 16, 2010 submission:

1725. To conduct a clinical trial that assesses the agreement between DaTscan imaging results and diagnostic outcomes among non-Caucasian and Caucasian patients. This trial will be designed and conducted in a manner that allows a comparison of the results between the non-Caucasian and Caucasian patients.

The timetable you submitted on December 30, 2010, states that you will conduct this trial according to the following schedule:

Final Protocol Submission:	December 31, 2011
Trial Completion:	April 30, 2013
Final Report Submission:	July 31, 2013

Our letters of September 8, 2009, and December 23, 2009, identified several issues pertinent to clarifying the safety or efficacy of your product. We previously asked you to propose a clinical trial to assess the impact of dopaminergic drugs upon DaTscan image results. The information you supplied in your November 16, 2010, submission resolved our issues pertinent to the need for this clinical trial. Hence, we do not request a post-marketing commitment for this trial.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

## **LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

## **MEDWATCH-TO-MANUFACTURER PROGRAM**

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment

instructions and program description details at  
<http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>.

**POST-ACTION FEEDBACK MEETING**

New molecular entities and new biologics qualify for a post-action feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call James Moore, Regulatory Project Manager, at (301) 796-2050.

Sincerely,

*{See appended electronic signature page}*

Charles Ganley, M.D.  
Director  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling  
Carton and Container Labeling